DgcityA first-in-human clinical trial in China has cut epileptic seizures by 92.6 per cent using chemogenetics, a technique that installs a molecular switch in brain cells and then controls it with a designer drug. The results offer one of the most promising paths in years for patients whose epilepsy resists ordinary medication.
Roughly a third of the world’s 50 million epilepsy patients do not respond adequately to available drugs. For people with focal epilepsy, where seizures arise from a specific patch of brain, surgeons sometimes remove the affected tissue in a craniotomy. That can work, but cutting into the brain carries a real risk of lasting deficits in speech, memory or movement, and many patients are not suitable candidates at all.
Chemogenetics takes a less destructive approach. Doctors deliver a harmless viral vector carrying a gene for a modified receptor into the seizure focus. The receptor sits on the surface of neurons but stays silent until patients take a specially designed drug that binds to almost nothing else in the body. When the drug is present, overactive cells in that patch of brain are gently dialled down. When the drug wears off, the tissue returns to normal.
The technique has worked remarkably well in mice and rats for more than a decade, but moving it into people has been slow. Questions lingered over whether the receptor would express safely in human neurons, whether enough cells would take up the gene, and whether the drug would reach the brain at predictable levels.
The new trial addressed those questions directly. Patients receiving the therapy saw their seizure frequency fall by an average of 92.6 per cent over the study period, with some participants reporting that attacks stopped altogether. The procedure avoided removing brain tissue, and the reversible nature of the switch gives doctors a level of control impossible with conventional surgery.
The numbers should be read with care. Early-phase trials involve small groups selected carefully for the procedure, and longer follow-up is needed to confirm that the effect holds for years rather than months. Researchers will also want to refine which patients and which seizure foci respond best.
Even so, the implications stretch beyond epilepsy. The same platform, sometimes called a kill switch for neural circuits, is being explored for chronic pain, movement disorders and psychiatric conditions where a defined brain region is overactive. A safe way to turn specific circuits up or down, temporarily and without permanent lesions, would be one of the most versatile tools in neurology.
For now, the result establishes what chemogenetics can do in a human brain. If larger trials confirm it, patients facing a choice between uncontrolled seizures and invasive surgery may finally get a third option, one that quiets the troublesome tissue without taking it away.
